Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Current Deferred Revenue (2016 - 2021)

Abeona Therapeutics has reported Current Deferred Revenue over the past 11 years, most recently at $296000.0 for Q4 2021.

  • Quarterly results put Current Deferred Revenue at $296000.0 for Q4 2021, changed 0.0% from a year ago — trailing twelve months through Dec 2021 was $296000.0 (changed 0.0% YoY), and the annual figure for FY2021 was $296000.0, changed 0.0%.
  • Current Deferred Revenue for Q4 2021 was $296000.0 at Abeona Therapeutics, roughly flat from $296000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for ABEO hit a ceiling of $2.6 million in Q4 2017 and a floor of $296000.0 in Q4 2018.
  • Median Current Deferred Revenue over the past 5 years was $296000.0 (2018), compared with a mean of $575444.4.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 331.89% in 2017 and later tumbled 88.62% in 2018.
  • Abeona Therapeutics' Current Deferred Revenue stood at $2.6 million in 2017, then tumbled by 88.62% to $296000.0 in 2018, then changed by 0.0% to $296000.0 in 2019, then changed by 0.0% to $296000.0 in 2020, then changed by 0.0% to $296000.0 in 2021.
  • The last three reported values for Current Deferred Revenue were $296000.0 (Q4 2021), $296000.0 (Q3 2021), and $296000.0 (Q2 2021) per Business Quant data.